Aldose reductase mediates NLRP3 inflammasome-initiated innate immune response in hyperglycemia-induced thp1 monocytes and male mice

Endocrinology

Volumn 158, Issue 10, 2017, Pages 3661-3675

  Pal, Pabitra B ^a   Sonowal, Himangshu ^a   Shukla, Kirtikar ^a   Srivastava, Satish K ^a   Ramana, Kota V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; CRYOPYRIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LYN; PROTEIN KINASE SYK; CALCIUM; CYTOKINE; IL1B PROTEIN, HUMAN; INFLAMMASOME; NLRP3 PROTEIN, MOUSE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INNATE IMMUNITY; MALE; MONOCYTE; MOUSE; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THP-1 CELL LINE; ANIMAL; CELL LINE; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; GENE SILENCING; GENETICS; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; OXIDATIVE STRESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALDEHYDE REDUCTASE; ANIMALS; CALCIUM; CELL LINE; CELL SURVIVAL; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPERGLYCEMIA; IMMUNITY, INNATE; IMMUNOBLOTTING; INFLAMMASOMES; INTERLEUKIN-1BETA; MALE; MICE; MONOCYTES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 85030622770     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2017-00294     Document Type: Article

References (56)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr, Sowers JR. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134-1146.
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-188.
3. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126-1167.
4. Paramel Varghese G, Folkersen L, Strawbridge RJ, Halvorsen B, Yndestad A, Ranheim T, Krohg-Sørensen K, Skjelland M, Espevik T, Aukrust P, Lengquist M, Hedin U, Jansson JH, Franśen K, Hansson GK, Eriksson P, SirsjoÄ. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc. 2016;5(5):e00301.
5. Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine. 2014;69(1):136-145.
6. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7): 677-687.
7. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62(1):194-204.
8. Aribi M, Moulessehoul S, Kendouci-Tani M, Benabadji AB, Hichami A, Khan NA. Relationship between interleukin-1beta and lipids in type 1 diabetic patients. Med Sci Monit. 2007;13(8): CR372-CR378.
9. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev. 2005;26(3):380-392.
10. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, Bhatnagar A, Srivastava SK. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation. 2006;114(17): 1838-1846.
11. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004;53(11):2910-2920.
12. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem. 2002;277(35): 32063-32070.
13. Saxena A, Tammali R, Ramana KV, Srivastava SK. Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. Antioxid Redox Signal. 2013;18(11):1249-1262.
14. Yadav UC, Aguilera-Aguirre L, Boldogh I, Ramana KV, Srivastava SK. Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma. Respir Res. 2011; 12:145.
15. Oka M, Matsumoto Y, Sugiyama S, Tsuruta N, Matsushima M. A potent aldose reductase inhibitor, (2S, 4S)-6-fluoro-20, 50-dioxospiro [chroman-4, 40-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by Xray crystallography. J Med Chem. 2000;43(12):2479-2483.
16. Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, Simon G, Busso N, So A. Xanthine oxidoreductase regulates macrophage IL1b secretion upon NLRP3 inflammasome activation. Nat Commun. 2015;6:6555.
17. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, DAgostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite b-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263-269.
18. He Y, Franchi L, Núnez G. TLR agonists stimulate Nlrp3-dependent IL-1b production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol. 2013; 190(1):334-339.
19. Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núnez G, Latz E, KastnerDL, Mills KH, Masters SL, Schroder K, Cooper MA, ONeill LA. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3): 248-255.
20. Ledoux J, Werner ME, Brayden JE, Nelson MT. Calcium-Activated potassium channels and the regulation of vascular tone. Physiology (Bethesda). 2006;21:69-78.
21. Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12(1):1-5.
22. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-820.
23. Dostert C, Ṕetrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876): 674-677.
24. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329): 221-225.
25. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004;53(Suppl 1):S110-S118.
26. Singh R, Devi S, Gollen R. Role of free radical in atherosclerosis, diabetes and dyslipidaemia: larger-Than-life. Diabetes Metab Res Rev. 2015;31(2):113-126.
27. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004;53(6): 1412-1417.
28. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxininteracting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136-140.
29. Li XN, Song J, Zhang L, LeMaire SA, Hou X, Zhang C, Coselli JS, Chen L, Wang XL, Zhang Y, Shen YH. Activation of the AMPKFOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes. 2009;58(10):2246-2257.
30. Hou X, Song J, Li XN, Zhang L, Wang X, Chen L, Shen YH. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun. 2010; 396(2):199-205.
31. Bondeva T, Wolf G. Reactive oxygen species in diabetic nephropathy: friend or foe? Nephrol Dial Transplant. 2014;29(11): 1998-2003.
32. Li A, Zhang S, Li J, Liu K, Huang F, Liu B. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-Associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. Mol Cell Endocrinol. 2016;434: 36-47.
33. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Srivastava SK. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes. 2005;54(3): 818-829.
34. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52(3):864-871.
35. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012;3:87.
36. Vedantham S, Ananthakrishnan R, Schmidt AM, Ramasamy R. Aldose reductase, oxidative stress and diabetic cardiovascular complications. Cardiovasc Hematol Agents Med Chem. 2012;10(3):234-240.
37. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006;55(10):2757-2762.
38. Abais JM, Xia M, Zhang Y, Boini KM, Li PL. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal. 2015;22(13):1111-1129.
39. Rajanbabu V, Galam L, Fukumoto J, Enciso J, Tadikonda P, Lane TN, Bandyopadhyay S, Parthasarathy PT, Cho Y, Cho SH, Lee YC, Lockey RF, Kolliputi N. Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2. Cell Immunol. 2015; 297(1):40-45.
40. Tozser J, Benko S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1beta production. Mediators Inflamm. 2016;2016:5460302.
41. Ṕetrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007;14(9):1583-1589.
42. Yaron JR, Gangaraju S, Rao MY, Kong X, Zhang L, Su F, Tian Y, Glenn HL, Meldrum DRK. K(+) regulates Ca(2+) to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis. 2015;6:e1954.
43. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61-70.
44. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner DL, Chae JJ. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492(7427):123-127.
45. Triantafilou K, Hughes TR, Triantafilou M, Morgan BP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. 2013; 126(Pt 13):2903-2913.
46. Clapham DE. Calcium signaling. Cell. 2007;131(6):1047-1058.
47. Saito K, Tolias KF, Saci A, Koon HB, Humphries LA, Scharenberg A, Rawlings DJ, Kinet JP, Carpenter CL. BTK regulates PtdIns-4, 5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity. 2003;19(5):669-678.
48. Viard P, Butcher AJ, Halet G, Davies A, Nürnberg B, Heblich F, Dolphin AC. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat Neurosci. 2004;7(9): 939-946.
49. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21(4):317-337.
50. Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, Olivier M. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases [published correction appears in PLoS Pathog. 2009 Sep;5(9)]. PLoS Pathog. 2009;5(8):e1000559.
51. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
52. Lin YC, Huang DY, Wang JS, Lin YL, Hsieh SL, Huang KC, Lin WW. Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization. J Leukoc Biol. 2015;97(5):825-835.
53. Karunanayake EH, Hearse DJ, Mellows G. Streptozotocin: its excretion and metabolism in the rat. Diabetologia. 1976;12(5): 483-488.
54. Karunanayake EH, Hearse DJ, Mellows G. The synthesis of [14C] streptozotocin and its distribution and excretion in the rat. Biochem J. 1974;142(3):673-683.
55. Yang B, Hodgkinson A, Oates PJ, Millward BA, Demaine AG. High glucose induction of DNA-binding activity of the transcription factor NFkappaB in patients with diabetic nephropathy. Biochim Biophys Acta. 2008;1782(5):295-302.
56. Zeng KW, Li J, Dong X, Wang YH, Ma ZZ, Jiang Y, Jin HW, Tu PF. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-kB and MAPK pathways. Toxicol Appl Pharmacol. 2013; 273(1):159-171.